Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 6, 2009, Pages 499-505

  Dransfield, Mark T ^a,i   Nahm, Moon H ^b   Han, MeiLan K ^c   Harnden, Sarah ^d   Criner, Gerard J ^e   Martinez, Fernando J ^c   Scanlon, Paul D ^f   Woodruff, Prescott G ^g   Washko, George R ^h   Connett, John E ^d   Anthonisen, Nicholas R ^h   Bailey, William C ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ NONE   (United States)

Author keywords

COPD; Immune responses; Immunization; Pneumococcal vaccines; Vaccination

Indexed keywords

7 VALENT DIPHTHERIA CONJUGATED PNEUMOCOCCAL POLYSACCHARIDE VACCINE; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARM CIRCUMFERENCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPSONIZATION; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SIDE EFFECT; SKIN DISCOLORATION; SKIN REDNESS; SWELLING; VACCINATION;

ADULT; AGE FACTORS; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; STREPTOCOCCUS PNEUMONIAE;

EID: 69949094422     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200903-0488OC     Document Type: Article

References (29)

1. Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
2. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542-1548. (Pubitemid 28307157)
3. Centers for Disease Control and Prevention. 2008. Meeting of the Advisory Committee on Immunization Practices (ACIP). November 24, 2008. (Accessed 2009 Jan 4). Available from: http://www.cdc.gov/vaccines/recs/acip/downloads/agenda- oct08.pdf
4. Fedson DS, Musher DM. 2003. Pneumococcal polysaccharide vaccine. In: Plotkin SA and Orenstein WA, editors. Vaccines, 4th ed. Philadelphia: Saunders. pp. 529-588.
5. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-2442. (Pubitemid 29526772)
6. Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, Raga X, Gomez F, Valdivieso E, Fuentes C, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008;26:1955-1962.
7. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-195.
8. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987;92:204-212. (Pubitemid 17118565)
9. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987;136:361-365. (Pubitemid 17015980)
10. Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine 2006;24:1408-1412. (Pubitemid 43222051)
11. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 2008;133:767-774.
12. Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004;22:1362-1371. (Pubitemid 38446912)
13. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-195.
14. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46:1015-1023. (Pubitemid 351589866)
15. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25:4029-4037. (Pubitemid 46616998)
16. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13:1004-1009.
17. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, Janoff EN. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998;178:431-440. (Pubitemid 28347925)
18. Jonsson S, Vidarsson G, Valdimarsson H, Schiffman G, Schneerson R, Jonsdottir I. Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. Eur Respir J 2002;20:813-818. (Pubitemid 35175114)
19. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, Plikaytis BD, Carlone GM. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281-288. (Pubitemid 29380185)
20. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-874.
21. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008;198:1019-1027.
22. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-248. (Pubitemid 29058113)
23. Johnson SE, Rubin L, Romero-Steiner S, Dykes JK, Pais LB, Rizvi A, Ades E, Carlone GM. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis 1999;180:133-140. (Pubitemid 29293927)
24. Musher DM, Phan HM, Watson DA, Baughn RE. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. J Infect Dis 2000;182:158-167.
25. Malley R, Lipsitch M, Bogaert D, Thompson CM, Hermans P, Watkins AC, Sethi S, Murphy TF. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. J Infect Dis 2007;196:928-935. (Pubitemid 47378944)
26. Nieminen T, Eskola J, Kayhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998;16:630-636. (Pubitemid 28112561)
27. Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, de Groot R, Hermans PW. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004;72:818-823. (Pubitemid 38166660)
28. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-1354.
29. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007;25:6164-6166. (Pubitemid 47088041)